vascular biogenics

Vascular Biogenics Ltd

VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first in class treatments for cancer.

VBL’s clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. To date, VBL has developed two programs based on these platforms – an oncology program and an anti-inflammatory program.

The Company’s lead oncology product candidate, VB-111, is a gene-based biologic for solid tumor indications that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. On September 2015, VBL reported full Phase 2 data from clinical trial of VB-111 in recurrent Glioblastoma (rGBM) at the European Cancer Conference, meeting the primary endpoint of statistically-significant increase in overall survival.